Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares news (Ticker: IINN), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares stock.
Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ: IINN) is at the forefront of developing innovative respiratory support technology as an alternative to invasive mechanical ventilation. The company's flagship product, INSPIRA ART100, is a breakthrough in Augmented Respiration Technology designed to maintain optimal oxygen levels in patients without the need for intubation and sedation. This technology is particularly significant in the treatment of respiratory failure and offers a less invasive option compared to traditional mechanical ventilation.
Inspira Technologies operates in various regions, including North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa. The company is involved in the research, development, manufacture, and marketing of proprietary respiratory care devices, aiming to transform the landscape of acute and neonatal care.
Recently, Inspira Technologies has announced several key developments:
- April 3, 2024: Commencement of a program to explore the use of the INSPIRA ART100 Device for an artificial womb for neonates requiring vital respiratory support.
- April 10, 2024: Collaborative development with Ennocure MedTech Ltd. on bio-electronic treatment to prevent bloodstream infections in ICU patients, showcasing a 100% reduction in bacterial growth within 24 hours in an in vitro study.
- April 16, 2024: Signing of a collaboration term sheet with Beilinson Hospital for the evaluation of the INSPIRA ART100 device in organ transplant procedures.
- April 25, 2024: Receiving CSA Certification of Compliance to U.S. standards for the INSPIRA ART100 device.
- May 2, 2024: Initiation of the production of the INSPIRA ART100 medical device by a leading technology company.
- May 28, 2024: Notification of 510(k) class II clearance from the U.S. FDA for the INSPIRA ART100.
Inspira's products are designed not only to enhance patient outcomes but also to reduce the costs and complications associated with traditional respiratory support methods. The INSPIRA ART100 system has received FDA clearance, marking a pivotal moment in the company's history. Other products in the pipeline, including the INSPIRA ART (Gen 2) and HYLA™ blood sensor, are poised to further revolutionize respiratory care once approved.
FAQ
What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What is the market cap of Inspira Technologies Oxy B.H.N. Ltd. Ordinary Shares (IINN)?
What does Inspira Technologies do?
What is the INSPIRA ART100?
What regions does Inspira Technologies operate in?
What recent programs has Inspira Technologies announced?
Who are some of Inspira Technologies' partners?
Has the INSPIRA ART100 received regulatory approval?
What makes the INSPIRA ART100 different from traditional mechanical ventilation?
What is the significance of the CSA Certification of Compliance?
What is the financial impact of mechanical ventilation in the U.S.?
Where can I find more information about Inspira Technologies?
